Nanobiosensors can detect biological molecules at the nanoscale, offering increased sensitivity and specificity. Companies in this field focus on the development, manufacturing, and commercialization of nanobiosensors for various healthcare applications.
Abbott (NYSE: ABT) Launched the FreeStyle Libre 3 system, a continuous glucose monitoring (CGM) system using nanobiosensors that eliminates the need for finger pricking for calibration.
Roche (OTCQX: RHHBY) Received FDA approval for their Elecsys IL-6 assay, a nanobiosensor-based test for rapid and accurate measurement of IL-6, a key inflammatory marker, in COVID-19 patients.
Bio-Techne (NASDAQ: BTECH) Launched their ExoPlex platform, a suite of nanobiosensor-based exosome isolation and analysis tools for early cancer detection and personalized medicine
Nano-Proprietary (OTCQB: NANP) Partnered with the University of California, San Diego to develop nanobiosensors for early detection of Alzheimer's disease.
Roche and AstraZeneca Partnered to develop and commercialize a novel nanobiosensor-based blood test for early-stage lung cancer detection.
MIT and Texas A&M University Collaborated to develop a microfluidic chip with built-in nanobiosensors for rapid and portable detection of infectious diseases.
List of Nanobiosensors in Healthcare Key Companies in the Market
Nanobiosensors in Healthcare Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)